Gene:
COMP
cartilage oligomeric matrix protein

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  thrombospondin-5
Alternate Symbols:  MED; THBS5
PharmGKB Accession Id: PA26744

Details

Cytogenetic Location: chr19 : p13.11 - p13.11
GP mRNA Boundary: chr19 : 18893583 - 18902114
GP Gene Boundary: chr19 : 18890583 - 18912114
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to COMP: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Human mutation. 2007. Marini Joan C, et al. PubMed

LinkOuts

Entrez Gene:
1311
OMIM:
132400
177170
600310
UCSC Genome Browser:
NM_000095
RefSeq RNA:
NM_000095
RefSeq Protein:
NP_000086
RefSeq DNA:
AC_000062
AC_000151
NC_000019
NG_007070
NT_011295
NW_001838484
NW_927195
UniProtKB:
COMP_HUMAN (P49747)
Ensembl:
ENSG00000105664
GenAtlas:
COMP
GeneCard:
COMP
MutDB:
COMP
ALFRED:
LO014686Z
HuGE:
COMP
Comparative Toxicogenomics Database:
1311
ModBase:
P49747
HumanCyc Gene:
HS02785
HGNC:
2227

Common Searches